Last reviewed · How we verify
HRS-8080 Tablets
HRS-8080 is an investigational small molecule with unknown mechanism of action in Phase 3 development.
At a glance
| Generic name | HRS-8080 Tablets |
|---|---|
| Sponsor | Shandong Suncadia Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available regarding the specific molecular mechanism of HRS-8080. As a Phase 3 candidate from Shandong Suncadia Medicine Co., Ltd., the drug is undergoing late-stage clinical evaluation, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases.
Approved indications
Common side effects
Key clinical trials
- A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy. (PHASE3)
- A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer (PHASE3)
- A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer (PHASE1, PHASE2)
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer (PHASE3)
- A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy Participants (PHASE1)
- Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer (PHASE1, PHASE2)
- A Phase 1, Randomized, Crossover Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy Subjects (PHASE1)
- A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRS-8080 Tablets CI brief — competitive landscape report
- HRS-8080 Tablets updates RSS · CI watch RSS
- Shandong Suncadia Medicine Co., Ltd. portfolio CI